Section 6 of 6
References
291 sources
- Achenbach and Saft (2021) (opens in a new tab)
- Aetna clinical policy bulletin 1073 (2026) (opens in a new tab)
- Ajitkumar et al. (2025) (opens in a new tab)
- American Academy of Neurology (2022) (opens in a new tab)
- American Academy of Neurology movement disorders quality measures (opens in a new tab)
- Anderson et al. (2018) (opens in a new tab)
- Andriessen et al. (2025) (opens in a new tab)
- Armstrong and Miyasaki (2012) (opens in a new tab)
- Austedo prescribing information (2025) (opens in a new tab)
- Bachoud-Lévi et al. (2019) (opens in a new tab)
- Baig et al. (2016) (opens in a new tab)
- Bardakjian et al. (2019) (opens in a new tab)
- Barer et al. (2023) (opens in a new tab)
- Bates et al. (2015) (opens in a new tab)
- Bayen et al. (2023) (opens in a new tab)
- Bean et al. (2014) (opens in a new tab)
- Bell (2026) (opens in a new tab)
- BioMarin statement, ROCTAVIAN market withdrawal (2026) (opens in a new tab)
- Blank (2023) (opens in a new tab)
- Boareto et al. (2025) (opens in a new tab)
- Boersema-Wijma et al. (2023) (opens in a new tab)
- Bombard et al. (2009) (opens in a new tab)
- Bruzelius et al. (2019) (opens in a new tab)
- Burgunder et al. (2011) (opens in a new tab)
- Byrne et al. (2017) (opens in a new tab)
- Caldeira Brás et al. (2026) (opens in a new tab)
- Carlozzi et al. (2016) (opens in a new tab)
- Carlozzi et al. (2017) (opens in a new tab)
- Caron et al. (2020) (opens in a new tab)
- Chen et al. (2024) (opens in a new tab)
- Christensen et al. (2022) (opens in a new tab)
- Claassen et al. (2017) (opens in a new tab)
- Claassen et al. (2021) (opens in a new tab)
- Claassen et al. (2022) (opens in a new tab)
- ClinicalTrials.gov NCT03628235 (opens in a new tab)
- ClinicalTrials.gov NCT04120493 (opens in a new tab)
- ClinicalTrials.gov NCT04120493 version 1 (opens in a new tab)
- ClinicalTrials.gov NCT04120493 version 33 (opens in a new tab)
- ClinicalTrials.gov NCT05243017 (opens in a new tab)
- ClinicalTrials.gov NCT05243017 version 1 (opens in a new tab)
- CMS Cell and Gene Therapy Access Model (2026) (opens in a new tab)
- Coppen and Roos (2017) (opens in a new tab)
- Crowell et al. (2021) (opens in a new tab)
- CTIS 2024-511766-37-00 (opens in a new tab)
- da Silva van der Laan et al. (2024) (opens in a new tab)
- DailyMed AUSTEDO prescribing information (2025) (opens in a new tab)
- DailyMed INGREZZA prescribing information (2026) (opens in a new tab)
- DailyMed XENAZINE prescribing information (2019) (opens in a new tab)
- Divino et al. (2013) (opens in a new tab)
- Dorey et al. (2016) (opens in a new tab)
- Ekkel et al. (2023) (opens in a new tab)
- El-Sourady et al. (2022) (opens in a new tab)
- EMA orphan designation EU/3/17/1957 (2018) (opens in a new tab)
- EMA questions and answers on withdrawal of Nurzigma application (2025) (opens in a new tab)
- Erwin et al. (2010) (opens in a new tab)
- Estevez-Fraga et al. (2021) (opens in a new tab)
- EU Clinical Trials Register 2020-001461-36 (opens in a new tab)
- Evans et al. (2013) (opens in a new tab)
- Evers et al. (2018) (opens in a new tab)
- Exuzides et al. (2021) (opens in a new tab)
- Exuzides et al. (2022a) (opens in a new tab)
- Exuzides et al. (2022b) (opens in a new tab)
- Exuzides et al. (2022c) (opens in a new tab)
- Farag et al. (2026a) (opens in a new tab)
- Farag et al. (2026b) (opens in a new tab)
- FDA externally controlled trials draft guidance (2023) (opens in a new tab)
- FDA Kebilidi summary basis for regulatory action (2024) (opens in a new tab)
- FDA long term follow-up after gene therapy guidance (2020) (opens in a new tab)
- FDA orphan drug designation record for AMT-130 (2017) (opens in a new tab)
- Ferreira et al. (2022) (opens in a new tab)
- Fisher and Hayden (2014) (opens in a new tab)
- Frank et al. (2025) (opens in a new tab)
- Frisch et al. (2026) (opens in a new tab)
- Furby et al. (2022) (opens in a new tab)
- Furr Stimming et al. (2023) (opens in a new tab)
- Furr Stimming et al. (2025) (opens in a new tab)
- Furr Stimming et al. (2026) (opens in a new tab)
- Fusilli et al. (2018) (opens in a new tab)
- Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (2015) (opens in a new tab)
- Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (2019) (opens in a new tab)
- Gokhale and Villa Zapata (2025) (opens in a new tab)
- Grimbergen et al. (2008) (opens in a new tab)
- Guzauskas et al. (2024) (opens in a new tab)
- Hagen (2023) (opens in a new tab)
- Hall et al. (2025) (opens in a new tab)
- Handsaker et al. (2025) (opens in a new tab)
- Harding (2026) (opens in a new tab)
- Harrison et al. (2023) (opens in a new tab)
- Hawkins et al. (2013) (opens in a new tab)
- Hawton et al. (2019) (opens in a new tab)
- Heemskerk and Roos (2012) (opens in a new tab)
- Helfand (2019) (opens in a new tab)
- Hensman Moss et al. (2017) (opens in a new tab)
- Hergert et al. (2021) (opens in a new tab)
- Hernandez (2024) (opens in a new tab)
- Hernandez (2025) (opens in a new tab)
- Herzog-Krzywoszanska and Krzywoszanski (2019) (opens in a new tab)
- Ho et al. (2009) (opens in a new tab)
- Hubers et al. (2012) (opens in a new tab)
- Hubers et al. (2013) (opens in a new tab)
- Huntington Study Group (1996) (opens in a new tab)
- Huntington Study Group (2006) (opens in a new tab)
- Huntington Study Group (2016) (opens in a new tab)
- Huntington's Disease Society of America (2011) (opens in a new tab)
- Huntington's Disease Society of America (2020) (opens in a new tab)
- Huntington's Disease Society of America Centers of Excellence (opens in a new tab)
- Huntington's Disease Society of America genetic testing and your rights (opens in a new tab)
- ICER (2026) (opens in a new tab)
- ICER draft scope (2026) (opens in a new tab)
- ICER Huntington's disease assessment page (2026) (opens in a new tab)
- ICER model analysis plan (2026) (opens in a new tab)
- ICER public comments on draft scope (2026) (opens in a new tab)
- ICER research protocol (2026) (opens in a new tab)
- ICER revised scope (2026) (opens in a new tab)
- ICER single and short-term therapies adaptations (2022) (opens in a new tab)
- Inbar et al. (2026) (opens in a new tab)
- Ingrezza prescribing information (2026) (opens in a new tab)
- Jahanshahi et al. (2021) (opens in a new tab)
- Johnson et al. (2018) (opens in a new tab)
- Jones et al. (2016) (opens in a new tab)
- Kachian et al. (2019) (opens in a new tab)
- Kay et al. (2016) (opens in a new tab)
- Kebilidi prescribing information (2024) (opens in a new tab)
- Keskin et al. (2019) (opens in a new tab)
- Keum et al. (2016) (opens in a new tab)
- Kim et al. (2024a) (opens in a new tab)
- Kim et al. (2024b) (opens in a new tab)
- Knott et al. (2024) (opens in a new tab)
- Ko et al. (2020) (opens in a new tab)
- Langbehn et al. (2004) (opens in a new tab)
- Langbehn et al. (2019) (opens in a new tab)
- Lee et al. (2022) (opens in a new tab)
- Lee et al. (2024) (opens in a new tab)
- Liu (2025) (opens in a new tab)
- MacLeod et al. (2013) (opens in a new tab)
- Marder et al. (2000) (opens in a new tab)
- Margolin et al. (2026) (opens in a new tab)
- Martinez-Horta et al. (2016) (opens in a new tab)
- Massey et al. (2021) (opens in a new tab)
- McColgan and Tabrizi (2018) (opens in a new tab)
- McColgan et al. (2023) (opens in a new tab)
- McLean et al. (2024) (opens in a new tab)
- Medina et al. (2022) (opens in a new tab)
- MedlinePlus (2020) (opens in a new tab)
- Mestre et al. (2009a) (opens in a new tab)
- Mestre et al. (2009b) (opens in a new tab)
- Mestre et al. (2018a) (opens in a new tab)
- Mestre et al. (2018b) (opens in a new tab)
- MHRA paediatric investigation plan waiver decision (2026) (opens in a new tab)
- Mills et al. (2024) (opens in a new tab)
- Miniarikova et al. (2016) (opens in a new tab)
- Miniarikova et al. (2017) (opens in a new tab)
- Miniarikova et al. (2018) (opens in a new tab)
- Minikel (2025) (opens in a new tab)
- Morais et al. (2022) (opens in a new tab)
- Morrison et al. (2011) (opens in a new tab)
- Mühlbäck et al. (2023) (opens in a new tab)
- Myshko (2022) (opens in a new tab)
- Myshko (2023) (opens in a new tab)
- Myshko (2024) (opens in a new tab)
- NINDS (2026) (opens in a new tab)
- Ogilvie et al. (2025) (opens in a new tab)
- Ogilvie et al. (2026) (opens in a new tab)
- Ohlmeier et al. (2019) (opens in a new tab)
- Oosterloo et al. (2024) (opens in a new tab)
- Oster et al. (2008) (opens in a new tab)
- Patel et al. (2023) (opens in a new tab)
- Patil et al. (2025) (opens in a new tab)
- Patil et al. (2026) (opens in a new tab)
- Paulsen et al. (2001) (opens in a new tab)
- Paulsen et al. (2014) (opens in a new tab)
- Pfizer press release, BEQVEZ approval (2024) (opens in a new tab)
- Phares et al. (2024) (opens in a new tab)
- Pollard et al. (2024) (opens in a new tab)
- Poprelka et al. (2025) (opens in a new tab)
- Pringsheim et al. (2012) (opens in a new tab)
- PTC Therapeutics (2026) (opens in a new tab)
- Quinn et al. (2020) (opens in a new tab)
- Rawlins et al. (2016) (opens in a new tab)
- Reilmann (2013) (opens in a new tab)
- Reilmann et al. (2014) (opens in a new tab)
- Reilmann et al. (2025) (opens in a new tab)
- Richardson et al. (2020) (opens in a new tab)
- Roche (2021) (opens in a new tab)
- Rodrigues and Ferreira (2017b) (opens in a new tab)
- Rodrigues et al. (2017a) (opens in a new tab)
- Rodrigues et al. (2020) (opens in a new tab)
- Rodriguez Santana et al. (2022) (opens in a new tab)
- Rodríguez Santana et al. (2025) (opens in a new tab)
- Rodríguez-Santana et al. (2021) (opens in a new tab)
- Rodríguez-Santana et al. (2023) (opens in a new tab)
- Roiboit and Stout (2026) (opens in a new tab)
- Roos (2010) (opens in a new tab)
- Saft et al. (2023) (opens in a new tab)
- Sampaio et al. (2024) (opens in a new tab)
- Sathe et al. (2021) (opens in a new tab)
- Sawant et al. (2024) (opens in a new tab)
- Schobel et al. (2017) (opens in a new tab)
- Sellers et al. (2020) (opens in a new tab)
- Shaw et al. (2022a) (opens in a new tab)
- Shaw et al. (2022b) (opens in a new tab)
- Silva-Paredes et al. (2019) (opens in a new tab)
- Smith et al. (2026) (opens in a new tab)
- Snowden (2017) (opens in a new tab)
- Sogorb-Gonzalez et al. (2021) (opens in a new tab)
- Sogorb-Gonzalez et al. (2024) (opens in a new tab)
- Sokol et al. (2022) (opens in a new tab)
- Sokol et al. (2023) (opens in a new tab)
- Solberg et al. (2018) (opens in a new tab)
- Spronck et al. (2019) (opens in a new tab)
- Spronck et al. (2021) (opens in a new tab)
- Stoker et al. (2022) (opens in a new tab)
- Tabrizi et al. (2011) (opens in a new tab)
- Tabrizi et al. (2013) (opens in a new tab)
- Tabrizi et al. (2020) (opens in a new tab)
- Tabrizi et al. (2022) (opens in a new tab)
- Tarolli et al. (2017) (opens in a new tab)
- Thomson et al. (2023) (opens in a new tab)
- Thorley et al. (2018) (opens in a new tab)
- To et al. (2022) (opens in a new tab)
- To et al. (2023) (opens in a new tab)
- Trundell et al. (2018) (opens in a new tab)
- Trundell et al. (2019) (opens in a new tab)
- uniQure expanded access policy (2024) (opens in a new tab)
- uniQure Form 10-K (2026) (opens in a new tab)
- uniQure Form 10-Q, third quarter 2026 (2026) (opens in a new tab)
- uniQure Huntington's disease program page (opens in a new tab)
- uniQure Phase I/II clinical trial page (opens in a new tab)
- uniQure presentation, four-year data (2026) (opens in a new tab)
- uniQure presentation, three-year topline results (2025) (opens in a new tab)
- uniQure press release, 24-month interim data (2024) (opens in a new tab)
- uniQure press release, BLA plan after Type B meeting (2026) (opens in a new tab)
- uniQure press release, BLA submission (2026) (opens in a new tab)
- uniQure press release, clinical update on first patients (2021) (opens in a new tab)
- uniQure press release, closing of sale to Genezen (2024) (opens in a new tab)
- uniQure press release, debt refinancing (2025) (opens in a new tab)
- uniQure press release, enrollment of first two cohorts (2022) (opens in a new tab)
- uniQure press release, FDA acceptance of BLA (2026) (opens in a new tab)
- uniQure press release, FDA alignment on accelerated approval (2024) (opens in a new tab)
- uniQure press release, FDA Fast Track designation (2019) (opens in a new tab)
- uniQure press release, FDA RMAT designation (2024) (opens in a new tab)
- uniQure press release, first European patients dosed (2022) (opens in a new tab)
- uniQure press release, first patients treated (2020) (opens in a new tab)
- uniQure press release, first quarter 2025 results (2025) (opens in a new tab)
- uniQure press release, four-year data (2026) (opens in a new tab)
- uniQure press release, full year 2022 results (2023) (opens in a new tab)
- uniQure press release, full year 2023 results (2024) (opens in a new tab)
- uniQure press release, full year 2025 results (2026) (opens in a new tab)
- uniQure press release, IND clearance (2019) (opens in a new tab)
- uniQure press release, interim data update (2023) (opens in a new tab)
- uniQure press release, low-dose cohort update (2022) (opens in a new tab)
- uniQure press release, MHRA pre-submission meeting (2026) (opens in a new tab)
- uniQure press release, pre-BLA meeting feedback (2025) (opens in a new tab)
- uniQure press release, pre-BLA meeting minutes (2025) (opens in a new tab)
- uniQure press release, preclinical publication (2019) (opens in a new tab)
- uniQure press release, preclinical publications (2021) (opens in a new tab)
- uniQure press release, sale of manufacturing facility to Genezen (2024) (opens in a new tab)
- uniQure press release, second quarter 2022 results (2022) (opens in a new tab)
- uniQure press release, second quarter 2025 results (2025) (opens in a new tab)
- uniQure press release, second quarter 2026 results (2026) (opens in a new tab)
- uniQure press release, statistical analysis plan and CMC alignment (2025) (opens in a new tab)
- uniQure press release, third quarter 2022 results (2022) (opens in a new tab)
- uniQure press release, third quarter 2025 results (2025) (opens in a new tab)
- uniQure press release, third quarter 2026 results (2026) (opens in a new tab)
- uniQure press release, three-year topline results (2025) (opens in a new tab)
- uniQure press release, Type A meeting minutes (2026) (opens in a new tab)
- uniQure press release, Type A meeting scheduled (2026) (opens in a new tab)
- uniQure press release, U.S. interim data (2023) (opens in a new tab)
- Vallès et al. (2021) (opens in a new tab)
- van der Bent et al. (2022) (opens in a new tab)
- van der Zwaan et al. (2022) (opens in a new tab)
- van Walsem et al. (2022) (opens in a new tab)
- Vonsattel et al. (1985) (opens in a new tab)
- Walker (2007) (opens in a new tab)
- Watkins et al. (2018) (opens in a new tab)
- Wesson et al. (2018) (opens in a new tab)
- Wexler et al. (2016) (opens in a new tab)
- Wheelock et al. (2003) (opens in a new tab)
- WHO Proposed INN List 125 (2021) (opens in a new tab)
- Willock et al. (2021) (opens in a new tab)
- Willock et al. (2023) (opens in a new tab)
- Wilson et al. (2024) (opens in a new tab)
- Winder et al. (2018) (opens in a new tab)
- Xenazine prescribing information (2017) (opens in a new tab)
- Yohrling et al. (2019) (opens in a new tab)
- Yohrling et al. (2020) (opens in a new tab)
- Young et al. (2026) (opens in a new tab)
- Youssov et al. (2022) (opens in a new tab)
- Youssov et al. (2025) (opens in a new tab)
- Yu et al. (2019) (opens in a new tab)
- Zhang et al. (2025) (opens in a new tab)